Valuation: TG Therapeutics, Inc.

Market Cap 8B 6.97B 6.43B 5.9B 11.22B 769B 11.41B 76.66B 30.1B 376B 30.02B 29.36B 1,296B P/E 2026 *
42.6x
P/E 2027 * 19.6x
Enterprise Value 8.03B 7B 6.46B 5.93B 11.27B 772B 11.45B 76.96B 30.22B 377B 30.14B 29.48B 1,301B EV / Sales 2026 *
8.52x
EV / Sales 2027 * 5.89x
Free-Float
88.55%
Yield 2026 *
-
Yield 2027 * -
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating MT
07-06 TG Therapeutics Initiates Phase 2 Trial Evaluating BRIUMVI In Patients With Treatment-Resistant Schizophrenia CI
07-06 TG Therapeutics Begins Phase 2 Trial of Briumvi in Treatment-Resistant Schizophrenia MT
06-09 TG Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02:00 PM
06-09 TG Therapeutics Reports Positive Topline Phase 1 Data For Subcutaneous BRIUMVI In Patients With Myasthenia Gravis and Initiates Potential Registration Directed Randomized Phase 2 Trial CI
06-09 TG Therapeutics Begins Phase 2 Myasthenia Gravis Trial MT
06-03 TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy MT
06-03 TG Therapeutics, Inc. Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous BRIUMVI CI
06-01 TG Therapeutics announces publication of post-hoc data from the phase 3 Ultimate I & II trials in treatment naive patients with relapsing forms of MS published in Frontiers in Immunology RE
06-01 TG Therapeutics, Inc. Publishes Post-Hoc Data from Phase 3 Ultimate I and Ii Trials Evaluating Briumvi in Treatment-Naïve Patients with Relapsing Multiple Sclerosis CI
05-27 Tg Therapeutics Announces Positive Topline Results from Phase 3 Enhance Trial CI
05-27 TG Therapeutics Says Phase 3 Briumvi Trial Met Main Goal MT
1 day+2.77%
1 week-2.84%
Current month+2.68%
1 month+13.91%
3 months+63.22%
6 months+90.96%
Current year+89.23%
1 week 53.35
Extreme 53.35
59.3
1 month 49
Extreme 49
59.3
Current year 26.76
Extreme 26.76
59.3
1 year 25.28
Extreme 25.28
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 28/12/2011
Director of Finance/CFO 44 28/12/2011
Investor Relations Contact - 30/11/2011
Director TitleAgeSince
Chairman 60 28/12/2011
Director/Board Member 79 29/02/2012
Director/Board Member 62 08/11/2012
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

8,325 0.0054%
06-10Free

Director

8,325 0.0054%
06-10Free

Director

8,325 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+2.77%-2.84%+44.94%+155.25% 7.78B
+0.35%-6.39%+44.70%+157.34% 1,028B
-2.69%-7.57%+57.52%+54.51% 611B
+0.44%-4.14%+27.46%+79.48% 432B
+0.98%-2.74%+28.13%+21.76% 323B
-0.34%-3.79%+26.52%+43.60% 277B
+1.63%-12.52%+17.86%+21.72% 257B
+3.39%+0.95%-25.43%-37.83% 217B
+0.86%-2.66%+20.63%+57.55% 192B
+1.28%-3.42%+17.49%+70.62% 161B
Average +1.20%-5.26%+25.98%+62.40% 350.61B
Weighted average by Cap. +0.78%-5.52%+32.98%+76.88%

Financials

2026 *2027 *
Net sales 942M 822M 758M 696M 1.32B 90.68B 1.34B 9.03B 3.55B 44.28B 3.54B 3.46B 153B 1.27B 1.11B 1.02B 936M 1.78B 122B 1.81B 12.16B 4.77B 59.58B 4.76B 4.66B 205B
Net income 207M 180M 167M 153M 291M 19.92B 295M 1.98B 779M 9.73B 777M 760M 33.55B 483M 421M 389M 357M 678M 46.47B 689M 4.63B 1.82B 22.69B 1.81B 1.77B 78.25B
Net Debt 31.06M 27.08M 24.99M 22.94M 43.6M 2.99B 44.32M 298M 117M 1.46B 117M 114M 5.03B -526M -459M -423M -389M -738M -50.63B -751M -5.04B -1.98B -24.73B -1.98B -1.93B -85.26B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
15/07/26 US$56.41 +2.77% 1,614,589
14/07/26 US$54.89 -0.22% 2,029,897
13/07/26 US$55.01 -3.69% 1,950,898
10/07/26 US$57.12 -3.28% 1,230,394
09/07/26 US$59.06 +3.20% 1,555,850
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
56.41USD
Average target price
58.00USD
Spread / Average Target
+2.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock